NEW YORK, Jan. 31 - GPC Biotech of Martinsried,
Under the agreement, GPC will use leadcode for mechanism-of-action studies on compounds for metabolic diseases. Financial terms of the deal were not disclosed.
LeadCode is a modified yeast two-hybrid technology designed to identify the interaction of small molecules with the full complement of human proteins, according to the company said. GPC applies this technology to its internal drug-discovery program for anticancer drugs.
Click here form more information.